Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In STAAR Surgical Company To Contact The Firm
Faruqi & Faruqi, LLP, , a leading minority and certified woman-owned national securities law firm, is investigating potential claims against STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA) and reminds investors of the October 19, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
If you suffered losses exceeding $50,000 investing in STAAR stock or options between February 26, 2020 and August 10, 2020 and would like to discuss your legal rights, please fill out the form below. There is no cost or obligation to you. You can also contact Faruqi & Faruqi partner James Wilson toll free at 877-247-4292 or 212-983-9330 (Ext. 1310) or by emailing him at firstname.lastname@example.org to discuss your rights and options.
The lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of all those who purchased STAAR common stock between February 26, 2020 and August 10, 2020 (the “Class Period”). The case, Alwazzan v. Staar Surgical Company et al., No. 20-cv-01533 was filed on August 19, 2020.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) its sales and growth in China; (2) its marketing spend; (3) its research and development expenses; and that as a result of the foregoing, (4) Defendants’ public statements were materially false and misleading at all relevant times.
On August 5, 2020, after the markets closed, STAAR reported its financial results for the second quarter ended July 3, 2020, filing a Form 10-Q and issuing a press release with the SEC. The Company reported net sales of $35.2 million (down 11% from the prior year quarter), and implantable Collamer® lenses (“ICL”) sales of $30.7 million (down 11% from the prior year quarter). STAAR reported a net loss of $0.03 per share, versus net income of $0.08 per share in the prior year quarter.
On this news, the Company's stock price fell from $61.81 per share on August 5, 2020 to $55.86 per share on August 6, 2020: a $5.95 or 90.37% drop.
Then, on August 11, 2020, analyst J Capital Research published a report in which it wrote that “[w]e think that STAAR Surgical has overstated sales in China by at least one-third, or $21.6 mln. That would mean that all of the company’s $14 mln in 2019 profit is fake.” The report continued that “[f]ake sales [in China] come at 100% margins and therefore translate directly into profit. That means that the roughly $21.6 mln in overstated Chinese sales in 2019 represent 152% of total company profit. In other words, without the fraud that we believe pervades the China business, STAAR is losing money.”
On this news, the Company's stock price fell from $51.42 per share on August 10, 2020 to $48.25 per share on August 11, 2020: a $3.17 or 6.16% drop.
STAAR Surgical Company (STAA)
* The submission of this form does not create an attorney-client relationship.
Filed on 08/17/2020
Lead Plaintiff Deadline 10/19/2020
685 Third Avenue 26th Floor
10017 New York, New York
Phone (212) 983-9330
Fax (212) 983-9331
Robert W. Killorin email@example.com Phone (404) 847-0617 Fax (404) 506-9534
James M. Wilson, Jr. firstname.lastname@example.org Phone (212) 983-9330 Fax (212) 983-9331